Avanir Pharmaceuticals (Nasdaq: AVNR ) is expected to report Q4 earnings on Dec. 12. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Avanir Pharmaceuticals's revenues will grow 173.0% and EPS will remain in the red.
The average estimate for revenue is $13.0 million. On the bottom line, the average EPS estimate is -$0.08.
Last quarter, Avanir Pharmaceuticals reported revenue of $10.5 million. GAAP reported sales were much higher than the prior-year quarter's $2.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at -$0.11. GAAP EPS were -$0.11 for Q3 versus -$0.13 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 94.7%, 50 basis points worse than the prior-year quarter. Operating margin was -139.6%, 50,750 basis points better than the prior-year quarter. Net margin was -142.6%, 50,520 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $40.8 million. The average EPS estimate is -$0.45.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 189 members out of 251 rating the stock outperform, and 62 members rating it underperform. Among 57 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 39 give Avanir Pharmaceuticals a green thumbs-up, and 18 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Avanir Pharmaceuticals is outperform, with an average price target of $5.40.
More Expert Advice from The Motley Fool
The Motley Fool's chief investment officer has selected his No. 1 stock for the next year. Find out which stock in our brand-new free report: "The Motley Fool's Top Stock for 2013
." I invite you to take a copy, free for a limited time. Just click here
to access the report and find out the name of this under-the-radar company.